

Caging NLRP3 tames inflammasome activity

Schroder, K., & Coll, R. C. (2021). Caging NLRP3 tames inflammasome activity. *Cell*, *184*(26), 6224-6226. https://doi.org/10.1016/j.cell.2021.11.035

Published in: Cell

Document Version: Peer reviewed version

Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal

Publisher rights Copyright 2021 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. - Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Title: Caging NLRP3 tames inflammasome activity

Authors:

Kate Schroder¹ and Rebecca C. Coll²

Affiliations:

¹Institute for Molecular Bioscience and IMB Centre for Inflammation and Disease Research, The University of Queensland, St. Lucia, Queensland 4072, Australia.

²The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Antrim, UK.

Abstract/summary:

How the danger sensor NLRP3 is activated is intensively debated. Using cryo-electron microscopy (EM) approaches, Andreeva and colleagues made the remarkable discovery that inactive NLRP3 forms a double ring of 12-16 monomers that shield its pyrin domains from the cytosol. We discuss this surprising new mechanism of inflammasome regulation.

Main text:

NACHT, LRR and PYD domain-containing protein 3 (NLRP3) is a cytosolic sensor of disrupted cellular homeostasis such as ionic flux. NLRP3 consists of an N-terminal pyrin (PYD) domain, a central NACHT domain that mediates ATP hydrolysis, and a C-terminal leucine rich repeat (LRR) domain (Figure 1A). Prior to activation, NLRP3 interacts with the protein NEK7, which facilitates NLRP3 signaling. Upon activation, NLRP3 assembles an inflammasome complex via PYD-PYD interactions with the adapter Apoptosis-associated speck-like protein containing a CARD (ASC), forming a platform for caspase-1 dimerization and activation. Active caspase-1 cleaves interleukin(IL)-1B, IL-18, and Gasdermin D (GSDMD), resulting in cytokine release, cell death and a highly inflammatory milieu. NLRP3driven inflammation accompanies the pathogenesis of many human diseases and NLRP3 is an attractive drug target (Swanson et al., 2019). Defining the structure and activation mechanisms of NLRP3 are thus of great interest. In this issue of Cell, Andreeva and colleagues (Andreeva et al., 2021) describe the first structure of full-length NLRP3 in its inactive state, providing new insights into how NLRP3 is prevented from inadvertent activation and providing a basis for rationale design of drugs to lock NLRP3 in its inactive state.

Cryo-EM imaging showed that amazingly, murine NLRP3 spontaneously forms a large oligomer consisting of a circular assembly of six to eight NLRP3 dimers. The six-dimer ring was resolved to 4.2 Å. Here, the NACHTs are barely in contact, while the LRRs of each NLRP3 molecule interlock with another monomer forming a pair; each pair forms a back-toback interface with other pairs to form a double ring (Figure 1B). This 'cage' structure is consistent with a pre-print cryo-EM structure of inactive human NLRP3 that forms a decamer (Hochheiser et al., 2021). Why different NLRP3 stoichiometries are reported is unclear but could reflect species differences or technical aspects.

Although the PYD domains could not be resolved by Andreeva and co-workers, their presumed density in the cryo-EM model suggests that the PYDs are contained inside the ring of NACHT-LRRs. PYD shielding within the NACHT-LRR cage may prevent aberrant interactions with ASC when NLRP3 is in its inactive, closed conformation (Figure 1B), and indeed, the double ring NLRP3 cage could not nucleate ASC. The NLRP3 NACHT-LRR domains bind to NEK7 (Sharif et al., 2019), but importantly, cannot do so within the NLRP3 cage because the NLRP3 double ring structure forms via LRR interactions along similar interfaces to those required for NEK7. A major structural rearrangement must occur for

NLRP3 to transit from the inactive cage structure to the active NLRP3 structure, which is likely a single ring formed by NACHT-NACHT interactions, akin to the NAIP-NLRC4 inflammasome (Duncan and Canna, 2018). It is possible that the cage may provide a mechanism for rapid NLRP3 activation, as NLRP3 monomers are assembled and on standby to sense a signal and convert to their active conformation.

Given that NLRP3 recruitment to the *trans*-Golgi network (TGN) may be necessary for NLRP3 signaling (Chen and Chen, 2018), the current study investigated the cellular location of the NLRP3 cage. Membrane extracts from inflammasome-resting cells indeed contained large NLRP3 oligomers consistent with the purified double ring, while cytosolic NLRP3 was monomeric or dimeric. The authors confirmed previous findings (Chen and Chen, 2018) that the NLRP3 polybasic motif (Figure 1A) mediates TGN membrane association, and discovered that this motif is also required for NLRP3 to form the double ring oligomer. Using a tag to force NLRP3 relocation to the Golgi membrane induced the double ring structure to form, suggesting that TGN membrane association is sufficient for NLRP3 cage assembly.

NLRP3-activating stimuli cause TGN dispersal concomitant with NLRP3 activation (Chen and Chen, 2018). Andreeva et al., report that NLRP3, and the NLRP3 cage in particular, are necessary for TGN dispersal, as an NLRP3 activator fails to induce TGN dispersal in *NLRP3*-deficient cells, or cells expressing an NLRP3 mutant that is unable to form the cage. Future work could address whether NLRP3 double ring cages are associated with other membrane types, and how this contributes to NLRP3 signaling. Endosomes are of particular interest as pre-prints report that NLRP3 activators disrupt endosomal trafficking (Lee et al., 2021; Zhang et al., 2021).

The cage structure has interesting implications for NLRP3 activation by ionic changes. The NLRP3 PYD-NACHT linker includes a fish-specific NACHT associated domain (FISNA; Figure 1A) that senses ionic flux and allows NLRP3 to adopt an active configuration (Tapia-Abellán et al., 2021) and an overlapping polybasic motif that enables membrane interaction (Chen and Chen, 2018). In the NLRP3 double ring structure, the arrangement of the PYD-NACHT linker will dictate how the PYD is positioned inside the cage structure. It is tempting to speculate that the FISNA must be exposed in the NLRP3 cage, so that it can sense ionic flux and respond by triggering the opening of NLRP3 monomers, and ATP hydrolysis, to enable NLRP3 to adopt its active quaternary conformation.

It is interesting to consider whether the NLRP3 cage structure is influenced by posttranslation modifications or natural variants. The authors modelled the LRR phosphorylation sites S803 and Y858 and propose that these may disrupt LRR interactions in the double ring structure. Point mutations in NLRP3 cause hyperactive signaling leading to autoinflammatory syndromes. It is possible that such LRR mutations, while rare, may alter the stability of the double ring structure to influence the NLRP3 activation threshold. The HSP90-SGT1 chaperone complex binds to NLRP3 LRRs and is required for maintaining NLRP3 in an inactive state that is poised for signaling (Mayor et al., 2007). Whether HSP90-SGT-1 associates with the NLRP3 cage or regulates its trafficking is unclear. Intriguingly, the NLRP3 LRR domain is reportedly dispensable for NLRP3 signaling (Hafner-Bratkovič et al., 2018). It must therefore be possible to activate NLRP3 without the prior formation of the double ring cage.

This study significantly advances our knowledge of NLRP3 biology by demonstrating how NLRP3 remains inactive, adding a novel regulatory step to a complex activation mechanism. Alongside two recent reports of NLRP3 structures containing the inhibitor MCC950 (Dekker et al., 2021; Hochheiser et al., 2021), this study will advance the rational design and development of new chemical entities that keep NLRP3 safely tamed inside its cage.

Acknowledgements

KS is supported by the National Health and Medical Research Council of Australia (Fellowship 1141131). RCC is supported by an Academy of Medical Sciences Springboard Award (SBF005\1104), and a Royal Society Research Grant (RGS\R1\201127).

Declaration of interests

KS and RCC are co-inventors on patent applications for NLRP3 inhibitors which have been licensed to Inflazome Ltd. KS served on the Scientific Advisory Board of Inflazome in 2016–2017 and is a consultant for Quench Bio and Novartis. RCC is a consultant for BioAge Labs.



Figure 1. Proposed model for NLRP3 activation leading to inflammasome signaling. A.

NLRP3 domain structure showing the pyrin domain (PYD), NACHT domain (NACHT), leucine rich repeats (LRRs), polybasic motif (Polybasic) and fish-specific NACHT associated domain (FISNA) **B.** An NLRP3 cage shields the PYDs from signaling in resting cells. When caged NLRP3 monomers sense an activation stimulus (e.g., nigericin), NLRP3 conformation rapidly switches to its active, single ring oligomeric structure that can recruit ASC and nucleate ASC polymerization. ASC fibers then recruit caspase-1 monomers, leading to caspase-1 clustering, proximity-induced dimerization, and activation, resulting in the generation of the proteolytically active inflammasome complex.

References

Andreeva, L., David, L., Rawson, S., Shen, C., Pasricha, T., Pelegrin, P., and Wu, H. (2021). Full-length NLRP3 forms oligomeric cages to mediate NLRP3 sensing and activation. Cell. 2021; **x:** xx-xx

Chen, J., and Chen, Z.J. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. 2019; **564**: 71-76

Dekker, C., Mattes, H., Wright, M., Boettcher, A., Hinniger, A., Hughes, N., Kapps-Fouthier, S., Eder, J., Erbel, P., Stiefl, N., et al. Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition. J. Mol. Biol. 2021; **433**: 167309

Duncan, J.A., and Canna, S.W. The NLRC4 Inflammasome. Immunol. Rev. 2018; **281:** 115–123

Hafner-Bratkovič, I., Sušjan, P., Lainšček, D., Tapia-Abellán, A., Cerović, K., Kadunc, L., Angosto-Bazarra, D., Pelegrin, P., and Jerala, R. NLRP3 lacking the leucine-rich repeat domain can be fully activated via the canonical inflammasome pathway. Nat. Commun. 2018; **9**: 5182

Hochheiser, I. V., Pilsl, M., Hagelueken, G., Moecking, J., Marleaux, M., Brinkschulte, R., Latz, E., Engel, C., and Geyer, M. Cryo-EM structure of the NLRP3 decamer bound to the cytokine release inhibitory drug CRID3. BioRxiv. 2021; doi: https://doi.org/10.1101/2021.07.22.453353

Lee, B., Hoyle, C., Green, J.P., Wellens, R., Martin-Sanchez, F., Williams, D., Seoane, P.I., Bennett, H., Adamson, A., Lopez-Castejon, G., et al. NLRP3 activation in response to disrupted endocytic traffic. BioRxiv. 2021; doi: https://doi.org/10.1101/2021.09.15.460426

Mayor, A., Martinon, F., De Smedt, T., Pétrilli, V., and Tschopp, J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat. Immunol. 2007; **8**: 497-503

Sharif, H., Wang, Ii, Ii Wang, W., Giri Magupalli, V., Andreeva, Iiudmila, Qiao, Q., Hauenstein, A. V, Wu, Z., Núñez, G., Mao, Y., et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature. 2019; **570**: 338-343

Swanson, K. V., Deng, M., and Ting, J.P.Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019; **19**: 477–489

Tapia-Abellán, A., Angosto-Bazarra, D., Alarcón-Vila, C., Baños, M.C., Hafner-Bratkovič, I., Oliva, B., and Pelegrín, P. Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation. Sci. Adv. 2021; **7**: eabf4468

Zhang, Z., Ran, L., Venditti, R., Liu, Z., Bonifacino, J.S., Matteis, M.A. De, Ricci, R., Biotechnology, M., Division, S.B., Kennedy, E., et al. (2021). Defective endosome-TGN retrograde transport promotes NLRP3 inflammasome activation. BioRxiv. 2021; doi: https://doi.org/10.1101/2021.09.14.460331